Diabetes is life long affliction that causes a person’s blood sugar level to become too high. With the two main types of diabetes, type 2 is far more common. Around 90% of all adults with diabetes have type 2.
Types
Type 2 is where the body is not creating enough insulin or the body is not reacting correctly to the insulin. This type usually requires the managing of medication, finding the right medication for each person can take time. Also many of the medications have side affects.
Type 1 is when the level of glucose in blood to be too high. This happens when the body isn’t producing enough of the hormone insulin which controls the levels of glucose in blood.
Both types are manageable with the correct advice and medication.
There are articles below that explore the condition in many different ways. Covering new research and evidence.
The University of Würzburg has shed light on the intricate mechanisms of insulin production in fruit flies, revealing surprising parallels with human physiology. This study offers crucial insights into how insulin-producing cells respond to metabolic changes, with potential implications for understanding and treating diabetes.
Dr Faz Chowdhury, CEO at Nemaura Medical (Nasdaq: NMRD), aims to stem the tide of the onset of diabetes and help to manage and reverse Type 2 diabetes using the world’s first daily-wear non-invasive CGM technology.
The idea is still at an early stage, but initial clinical study results show that immunotherapy against type 1 diabetes could function as a 'diabetes vaccine.'
Gary Davies, from Sandvik Materials Technology, explains how medical wires are helping patients monitor blood glucose levels without the need for daily testing.
A new study from Children's Hospital Los Angeles has revealed a surge of pediatric patients presenting with diabetic ketoacidosis throughout the COVID-19 pandemic.
Dr Faye Riley, Senior Research Communications Officer at Diabetes UK, highlights how immunotherapy is raising hopes for the next big breakthrough in type 1 diabetes.
Dr Eugene Durenard, CEO of Hyperbolic Holdings GmbH discusses promising emerging technologies in the field of early detection and prevention of major chronic diseases.
Professor Dr Apichart Vanavichit, at the Rice Science Center, reveals the hard solution to develop low glycemic rice for diabetes, starting with comment on soft-texture white rice as a health risk factor.
